SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The ...

Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...

Stelo is meant for those with Type 2 diabetes as well as people who want more insight into their blood sugar levels. Here's how biosensors are growing in 2024. Jessica was a writer on the Wellness ...

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

Credit: Dexcom. The Dexcom Stelo Glucose Biosensor System is an integral CGM intended for individuals 18 years of age and older with or without diabetes who are not on insulin. The Food and Drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

An over-the-counter continuous glucose monitoring (CGM) solution developed by Dexcom called Stelo has received clearance from the Food and Drug Administration (FDA). Available without the need for a ...

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access ...